(Total Views: 625)
Posted On: 05/13/2020 3:58:23 PM
Post# of 153915
WOW!
The toxicity of these agents and many others is under evaluation in clinical trials to determine their effectiveness against COVID-19. Data has already begun to be shared with the FDA from some clinical trials, such as leronlimab, which had data recently published in a pre-print manuscript online. The FDA intends to engage with pharmaceutical sponsors and other government agencies to facilitate patient access to these potential treatments as soon as favorable results are seen.>>
https://www.targetedonc.com/view/fda-advances...-treatment
The toxicity of these agents and many others is under evaluation in clinical trials to determine their effectiveness against COVID-19. Data has already begun to be shared with the FDA from some clinical trials, such as leronlimab, which had data recently published in a pre-print manuscript online. The FDA intends to engage with pharmaceutical sponsors and other government agencies to facilitate patient access to these potential treatments as soon as favorable results are seen.>>
https://www.targetedonc.com/view/fda-advances...-treatment
(1)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
